Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Residual macrovascular risk in 2013: what have we learned?
Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, Barter P, Betteridge J, Bruckert E, Cuevas A, Farnier M, Ferrannini E, Fioretto P, Genest J, Ginsberg HN, Gotto AM Jr, Hu D, Kadowaki T, Kodama T, Krempf M, Matsuzawa Y, Núñez-Cortés JM, Monfil CC, Ogawa H, Plutzky J, Rader DJ, Sadikot S, Santos RD, Shlyakhto E, Sritara P, Sy R, Tall A, Tan CE, Tokgözoğlu L, Toth PP, Valensi P, Wanner C, Zambon A, Zhu J, Zimmet P; Residual Risk Reduction Initiative (R3i). Fruchart JC, et al. Among authors: farnier m. Cardiovasc Diabetol. 2014 Jan 24;13:26. doi: 10.1186/1475-2840-13-26. Cardiovasc Diabetol. 2014. PMID: 24460800 Free PMC article. Review.
[Obesity and cardiovascular risk].
Krempf M, Farnier M. Krempf M, et al. Among authors: farnier m. Ann Endocrinol (Paris). 2001 Sep;62(4 Pt 2):S23-9. Ann Endocrinol (Paris). 2001. PMID: 11787368 Review. French.
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.
Kastelein JJ, Robinson JG, Farnier M, Krempf M, Langslet G, Lorenzato C, Gipe DA, Baccara-Dinet MT. Kastelein JJ, et al. Among authors: farnier m. Cardiovasc Drugs Ther. 2014 Jun;28(3):281-9. doi: 10.1007/s10557-014-6523-z. Cardiovasc Drugs Ther. 2014. PMID: 24842558 Free PMC article. Clinical Trial.
Combination therapy in dyslipidemia: where are we now?
Catapano AL, Farnier M, Foody JM, Toth PP, Tomassini JE, Brudi P, Tershakovec AM. Catapano AL, et al. Among authors: farnier m. Atherosclerosis. 2014 Nov;237(1):319-35. doi: 10.1016/j.atherosclerosis.2014.09.026. Epub 2014 Sep 30. Atherosclerosis. 2014. PMID: 25299967 Review.
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
Aguiar C, Alegria E, Bonadonna RC, Catapano AL, Cosentino F, Elisaf M, Farnier M, Ferrières J, Filardi PP, Hancu N, Kayikcioglu M, Mello E Silva A, Millan J, Reiner Ž, Tokgozoglu L, Valensi P, Viigimaa M, Vrablik M, Zambon A, Zamorano JL, Ferrari R. Aguiar C, et al. Among authors: farnier m. Atheroscler Suppl. 2015 Sep;19:1-12. doi: 10.1016/S1567-5688(15)30001-5. Atheroscler Suppl. 2015. PMID: 26315511
Statin combination therapy and cardiovascular risk reduction.
Toth PP, Farnier M, Tomassini JE, Foody JM, Tershakovec AM. Toth PP, et al. Among authors: farnier m. Future Cardiol. 2016 May;12(3):289-315. doi: 10.2217/fca-2015-0011. Epub 2016 Apr 15. Future Cardiol. 2016. PMID: 27079178 Review.
204 results